Massachusetts General Hospital Bellingham, MA, United States
H. Ababneh1, J. Barnes2, S. Jain2, and C. G. Patel1; 1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Purpose/Objective(s): To asses the long term in-field response and toxicity profile of patients with cutaneous lymphomas who received surface applicator brachytherapy. Materials/
Methods: A retrospective study was conducted for consecutive patients with Cutaneous B- and T-cell lymphomas (CBCL and CTCL) who were treated with surface applicator high-dose-rate (HDR) brachytherapy between 2000 and 2023 at a single institution. The in-field response was evaluated using post-brachytherapy imaging and/or clinical assessment. Results: A total of 16 patients with CBCL and CTCL who received surface applicator HDR brachytherapy were identified (10 CTCL, and 6 CBCL) with a median follow-up from the date of diagnosis of 5.5 years [interquartile range (IQR): 2.6-10.8 years]. Thirteen patients were male and 3 were female, with a median age of 62 years (range, 23-73 years) at the time of diagnosis. The total irradiated sites were 52. Sites of RT include: head and neck (40), lower extremities (9), and upper extremities (3). The median dose/fractionation were 8 Gy (range, 4-30 Gy) and 2 fractions (range, 2-15 fractions). The in-field responses of the 48 evaluable sites were as follows: complete response (n=39, 81%), partial response (n=6, 13%), and in-field progression (n=3, 6%); the remaining sites were not evaluable because the patients were lost to follow up after radiation treatment. The 3-year in-field progression-free survival rate was 87%. No significant RT-related toxicities were identified. At the time of the last follow-up, 13 patients remained alive and 3 patients succumbed to progressive lymphoma. Conclusion: High-dose-rate brachytherapy demonstrates significant efficacy in treating cutaneous lymphomas, achieving high local control rates, and is well tolerated, particularly at lower radiation doses
